Publications en collaboration avec des chercheurs de GlaxoSmithKline (United Kingdom) (8)

2020

  1. Hakin-1, a new specific small-molecule inhibitor for the E3 ubiquitin-ligase Hakai, inhibits carcinoma growth and progression

    Cancers, Vol. 12, Núm. 5

2017

  1. Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B

    Journal of Computer-Aided Molecular Design, Vol. 31, Núm. 10, pp. 915-928

2016

  1. An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies

    Drug Safety, Vol. 39, Núm. 1, pp. 29-43

  2. Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 79-87

  3. Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): A methodological approach to assess consistencies across databases from the PROTECT-EU project

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 66-78

  4. Stepwise Simulation of 3,5-Dihydro-5-methylidene-4H-imidazol-4-one (MIO) Biogenesis in Histidine Ammonia-lyase

    Biochemistry, Vol. 55, Núm. 41, pp. 5854-5864

  5. Understanding inconsistency in the results from observational pharmacoepidemiological studies: The case of antidepressant use and risk of hip/femur fractures

    Pharmacoepidemiology and Drug Safety, Vol. 25, pp. 88-102

2014

  1. Bridging differences in outcomes of pharmacoepidemiological studies: Design and first results of the PROTECT project

    Current Clinical Pharmacology, Vol. 9, Núm. 2, pp. 130-138